Literature DB >> 19860736

Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.

Chrisostomos Prodromou1.   

Abstract

Hsp90 is involved in the maturation and activation of client proteins. Often these are key proteins involved in signal transduction and regulatory pathways that in a mutated and/or deregulated form sustain an oncogenic cellular state. Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity. The requirement for the Hsp90 chaperone machine to drive the malignancy makes Hsp90 a prime anticancer target, an 'axle in a wheel' that when disrupted has been shown to be effective in killing cancerous cells. This review aims to identify potential drug targets, based on the current structural knowledge of the Hsp90-chaperone machine, that could be targeted with the aim of disrupting its functioning and promoting an anti-cancer activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860736     DOI: 10.2174/156802609789895656

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  13 in total

1.  Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays.

Authors:  Francisco J Diaz; Peter R McDonald; Anuradha Roy; Byron Taylor; Ashleigh Price; Jessica Hall; Brian S J Blagg; Rathnam Chaguturu
Journal:  Comb Chem High Throughput Screen       Date:  2013-03       Impact factor: 1.339

2.  Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Authors:  Jooeun Bae; Aditya Munshi; Cheng Li; Mehmet Samur; Rao Prabhala; Constantine Mitsiades; Kenneth C Anderson; Nikhil C Munshi
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

3.  Hsp90 interacts with inducible NO synthase client protein in its heme-free state and then drives heme insertion by an ATP-dependent process.

Authors:  Arnab Ghosh; Mamta Chawla-Sarkar; Dennis J Stuehr
Journal:  FASEB J       Date:  2011-02-25       Impact factor: 5.191

Review 4.  Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.

Authors:  Harvey Schwartz; Brad Scroggins; Abbey Zuehlke; Toshiki Kijima; Kristin Beebe; Alok Mishra; Len Neckers; Thomas Prince
Journal:  Cell Stress Chaperones       Date:  2015-06-13       Impact factor: 3.667

5.  Hsp90 inhibition: elimination of shock and stress.

Authors:  Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-07-01       Impact factor: 2.823

6.  Modulating Heat Shock Proteins 70 and 90 Expression by Low Power Laser Irradiation (635nm and 780nm) in Jurkat E6.1 T-lymphocyte Leukemia Cell Line.

Authors:  Ali Hussein Ad'hiah; Layla Mohammed Hassan Al-Ameri; Amel Mustfa Maki; Qiuyu Wang; Mayada Hameed ALQaisi
Journal:  J Lasers Med Sci       Date:  2015

7.  Novobiocin Analogues That Inhibit the MAPK Pathway.

Authors:  Jessica A Hall; Sahithi Seedarala; Huiping Zhao; Gaurav Garg; Suman Ghosh; Brian S J Blagg
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

8.  Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.

Authors:  Jessica A Hall; Sahithi Seedarala; Nichole Rice; Lucas Kopel; Fathi Halaweish; Brian S J Blagg
Journal:  J Nat Prod       Date:  2015-03-10       Impact factor: 4.050

9.  Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.

Authors:  Sheena D Singh-Babak; Tomas Babak; Stephanie Diezmann; Jessica A Hill; Jinglin Lucy Xie; Ying-Lien Chen; Susan M Poutanen; Robert P Rennie; Joseph Heitman; Leah E Cowen
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

10.  Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition.

Authors:  Jean-Philippe Lambert; Gordana Ivosev; Amber L Couzens; Brett Larsen; Mikko Taipale; Zhen-Yuan Lin; Quan Zhong; Susan Lindquist; Marc Vidal; Ruedi Aebersold; Tony Pawson; Ron Bonner; Stephen Tate; Anne-Claude Gingras
Journal:  Nat Methods       Date:  2013-10-27       Impact factor: 28.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.